© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Every drug has a backstory, and Pirfenidone’s journey started in the late twentieth century when researchers began searching for ways to slow down the relentless march of fibrosis, especially in organs like the lung. Early studies stuck out because doctors noticed that certain compounds could actually tamp down the signals that cause tissue scarring. Pirfenidone landed on the radar through its unique ability to interfere with these signals, especially after animal studies showed that it could dial back inflammation and collagen buildup. Fast-forward a couple decades, and persistent clinical trials delivered the news that people with idiopathic pulmonary fibrosis (IPF) lived longer and breathed easier with this small molecule on board.
Pharmaceutical companies now turn Pirfenidone into oral capsules and tablets, making it accessible to patients worldwide. The medicine works by blocking growth factors and inflammatory messengers inside the lungs. Doctors tend to reach for it when someone faces progressive lung scarring that can’t be explained by infections, autoimmune disease, or environmental exposures. The drug isn’t just a lucky accident—it follows rigorous batches and meets global standards for purity, dosage, and stability, blending science and care in every pill.
Pirfenidone carries the chemical formula C12H11NO and tips the scales at a molecular weight just shy of 185.23 g/mol. Most folks picture the compound as an off-white powder. Its melting point sits between 109°C and 111°C, and it dissolves well enough in alcohol, slightly in water, and less so in other non-polar liquids. The aromatic rings in its structure help it pass into blood and tissues, which means it can reach the tiny pockets within scarred organs. In practice, this stability and solubility keep Pirfenidone active after long production and shipping cycles.
Drug makers mark each Pirfenidone container with precise concentration, batch number, manufacturing date, and expiration details. Tablets usually pack a 200- to 801-milligram dose, tailored for twice or thrice-daily use. Safety seals, blister packaging, and stern storage advice keep it fresh: cool, dry shelves, and no sunlight. Labels warn users about liver monitoring and avoid mixing Pirfenidone with some antibiotics or foods that may tip toxin levels. Pharmacies in the US, Europe, and Asia follow rules set by watchdogs like the FDA and EMA to make sure what reaches the patient matches what’s on the label.
Every batch starts with 5-methyl-1-phenyl-2-(1H)-pyridone, the key piece in Pirfenidone’s blueprint. Chemists couple this pyridone with benzene derivatives through condensation reactions, relying on acid, heat, and sometimes a dash of catalyst to speed things up. Purification steps—recrystallization, filtration, and chromatography—pull out the clean compound. Once dried, the powder heads to blending and tableting lines, where fillers and binders turn the raw drug into a pill patients can swallow. Throughout the process, labs measure for purity and check for leftover solvents so no contamination sneaks through.
Researchers tweak Pirfenidone’s chemical backbone to hunt for new benefits or knock out unwanted effects. Swapping out side groups or tweaking the pyridone ring changes how the molecule moves through the body or sticks to its targets. Some scientists have attached fluorescent tags to Pirfenidone for tracking in lab studies, while others have built slow-release coatings so patients can take fewer pills each day. Not every modification wins the safety race, but this ongoing work sometimes turns up forms with better absorption or longer impact.
Pirfenidone also answers to names like 5-methyl-1-phenyl-2-(1H)-pyridone—or by its branded label, Esbriet, in clinics around the world. Japanese patients might see the trade name Pirespa. Doctors sometimes lump it under broader categories like anti-fibrotic or immunomodulatory agents in medical charts and research papers.
Working with Pirfenidone in labs and factories calls for careful gear—protective gloves, fume hoods, and dust control—to avoid inhalation or skin exposure. Tablets get packaged in tamper-resistant containers, with instructions on handwashing and safe disposal, to lower risk for both handlers and the environment. Companies train staff to handle spills and accidental exposures with calcium hydroxide and proper ventilation, keeping everyone downstream protected. At home, patients get regular blood tests to watch for signs of liver strain or skin reactions, since light sensitivity and mild gastrointestinal symptoms show up in a slice of the user population.
The biggest win for Pirfenidone so far has come from the treatment of idiopathic pulmonary fibrosis, a condition where scar tissue slowly chokes off lung capacity. Beyond IPF, some doctors and labs test Pirfenidone in kidney, liver, and cardiac diseases marked by similar scar-building processes. Preclinical work hints at activity in skin and eye disorders, opening new doors for future clinical trials. Hospitals in dozens of countries rely on Pirfenidone as one line of defense against the tide of chronic scarring illnesses.
Pharma companies and academic labs race to understand just how Pirfenidone tweaks cell behavior. Researchers track which signaling pathways it quiets and which tissues it saves from scarring. Some add Pirfenidone to combinations with other antifibrotics or immunotherapies in lab dishes and animal models, watching for clues about synergy or resistance. Advanced imaging and genetic profiling sharpen the picture, revealing why some patients respond better than others and who stands to gain the most. Investment in R&D often spills into patent filings, joint ventures, and international trials, so progress spreads beyond any one company or border.
Every new medicine takes years to pass toxicology hurdles and Pirfenidone is no exception. Researchers used rats, dogs, and cell cultures to tease out where and how Pirfenidone might stress organs. Most test doses land below the thresholds for acute toxicity, though elevated liver enzymes and upset stomachs crop up in some long-term courses. Light sensitivity proves notable: both in animal models and some patient groups, skin reacts more strongly to UV rays, so doctors warn against too much sun. Occasional studies suggest rare liver problems can flare in susceptible people. Review boards track these events closely, demanding regular safety updates from drug makers.
Looking ahead, the horizon for Pirfenidone stretches well beyond pulmonary fibrosis. Genetics-driven medicine may help pinpoint which patients benefit most from antifibrotics, so treatment decisions become more personal. New formulations, including once-daily pills or even inhaled forms, could make dosing easier while trimming side effects. Partnerships between biotech, academic centers, and health systems will expand Pirfenidone trials into rare, organ-specific diseases. Long-term, insights from Pirfenidone might unlock other anti-fibrotic classes that slow or even reverse scarring across a wider range of conditions, giving hope to thousands with no great options today.
Pirfenidone changes the game for people facing one of lung medicine’s toughest diagnoses: idiopathic pulmonary fibrosis, known as IPF. I came across stories from families and patients clutching at hope after being told that their lungs would keep scarring until they could barely draw a breath. IPF scars lungs and makes everyday tasks—walking, chatting, climbing a few steps—feel almost impossible. Doctors and patients now look toward Pirfenidone as a lifeline, not a cure, but a way to slow this relentless process down.
Pirfenidone steps in by fighting the fibrosis that builds up in the lungs. Scarring doesn’t just mean a few rough patches—it means less oxygen enters the bloodstream, and the lungs stiffen. The drug hits at the biological processes that fire up scarring and inflammation. This means it helps people keep more of their breathing ability over time. In my experience in healthcare, watching a medication give someone back control—helping them preserve the simple act of breathing—is invaluable.
Trust doesn’t come easy when treatments carry risks and hope. The Food and Drug Administration gave its approval after reviewing years of data. Trusted clinical trials involving thousands of real patients, not just lab work, support its use. The side effects—like stomach trouble, or skin sensitivity in sunlight—aren’t minor, but most patients and doctors feel that the trade-off favors a slower disease over a fast-changing, shrinking world.
Not every patient can walk into a pharmacy and pick up Pirfenidone without worry. The cost of this drug hits families hard, even with insurance stepping in. Many advocacy groups press for more affordable therapies, and insurance companies face pressure to loosen restrictions. Out-of-pocket prices mean some patients simply cannot start or stick to the treatment.
Support groups, online forums, and lung disease specialists often talk about the frustration of battling both a diagnosis and a broken health system. Friends of mine in pulmonology clinics tell me about having tough conversations: convincing insurance, filling out stacks of forms, searching for patient assistance programs. For a drug with proven results in slowing lung function loss, gatekeeping feels especially unfair.
Pirfenidone offers a chance for more birthdays, more walks, and more stories shared between families. Beyond just prescribing the drug, teams work with patients to make sure nutrition supports their lungs, exercise fits safely into their days, and mental health doesn’t fall through the cracks. Education about side effects—real, practical tips for beating nausea or protecting skin—makes all the difference. I’ve seen more lives changed by honest conversations between care teams and patients than by any prescription alone.
Scientists keep searching for better answers—a cure, not just a slowdown. Pirfenidone stands out today because it holds back a disease that just a decade ago meant almost certain, rapid decline. Continued research and louder patient advocacy will likely push for both improved drugs and better access. Until something new comes along, Pirfenidone reminds us that medical progress makes the hard days with IPF just a bit more manageable.
Living with idiopathic pulmonary fibrosis doesn’t leave a lot of choices for medication. Pirfenidone is one option many folks get familiar with, including myself and the people I’ve worked alongside in support groups. This drug slows the scarring in the lungs, which gives hope for a better quality of life. It comes with a catch: side effects that can get in the way of feeling “normal” again.
Talking with friends who’ve taken pirfenidone, one thing stands out—almost no one escapes stomach issues. Nausea hits hard, often making mealtime a drag. Some report vomiting, not just queasiness. Many folks feel less interested in food altogether, and that weight loss isn’t always healthy.
Skin problems pop up next most often. I’ll never forget sharing stories at a group meeting—one woman looked sunburned every afternoon. Pirfenidone makes skin extra sensitive. Even short walks in weak sun triggered rashes and peeling, so people start hiding indoors and covering up more.
Another bit folks mention is feeling tired all the time. Fatigue shows itself in sneaky ways. You think it’s bad lungs, but the medicine doesn’t do any favors here. Some folks I know switched to taking it after meals or at bedtime to avoid the worst of the drag.
Dizziness raised real concern after I got up too fast one morning and nearly fell. It didn’t go away until lunchtime. Lightheaded spells may not be the most talked-about issue, but they send plenty of people back to their doctor.
The liver keeps an eye on what goes through the body, and pirfenidone puts it to work. Routine blood tests matter, because liver markers can creep up without warning. A friend’s doctor caught rising numbers before any symptoms showed up, and she got switched to something safer.
Some people report shortness of breath, which gets confusing because this is also a symptom of fibrosis. If this side effect changes suddenly or feels different, it’s no time to brush it off. The same goes for swelling, yellowing of the eyes or skin, or dark-colored urine—urgent calls to the doctor save lives here.
Ignoring these problems only makes them worse. I’ve watched support group members delay talking to their providers, hoping side effects go away on their own. This ended in hospital visits for more than one person. Doctors can adjust dosing, add anti-nausea medication, or suggest ways to protect skin from the sun.
Education really makes a difference. My own experience teaches me that having written information handy, asking questions, and keeping a notebook of any reactions makes the whole situation much more manageable. For many, side effects settle down over time; for others, switching medication or adjusting lifestyle helps.
No one chooses pirfenidone expecting a trouble-free road. Sharing stories and advice gives people practical tools to handle what comes, which keeps hope alive and puts some power back in the hands of those dealing with disease.
Living with pulmonary fibrosis brings a lot of change into daily routines, both physically and mentally. Pirfenidone slows scarring in the lungs, so every dose means a hopeful step toward breathing easier. Taking this medicine the right way can help people keep up with family, work, and daily activities, which builds a sense of control when life starts feeling unpredictable.
Pirfenidone comes as a pill, meant to be swallowed whole with food. Skipping meals or taking it on an empty stomach can spark stomach pain or nausea. People with busy schedules — who grab a quick breakfast or sometimes skip lunch — often forget a pill, then double up, then hit rough side effects. Eating something with the medicine, even a piece of toast, gives a buffer against an upset stomach.
Doctors usually start patients at a lower dose, then build up to the full amount over a couple of weeks. The adjustment happens slowly for one good reason: sudden high doses will often cause more tiredness, loss of appetite, and skin rashes. It’s tempting to rush, hoping for faster benefits, but patience here protects from a rough ride later on. Most folks I’ve talked to keep a log, just a scrap of paper or a note on their phone, to track doses and meals. It’s a small act that adds a sense of control.
Pirfenidone makes skin more sensitive. Even short walks on sunny days can leave people with bad sunburn or serious rashes. Farmers, delivery drivers, even dog walkers run into trouble if they slip up. Sunscreen, hats, and long sleeves help, but it’s not foolproof. Picking shaded routes, planning errands early or late, and carrying a spare shirt make a bigger difference than most folks expect. I’ve learned that sharing the reality of sunburn risks with friends makes them more understanding when you cancel last-minute or need a quick change in the plan.
Nausea, heartburn, and skin issues show up for plenty of people on Pirfenidone. Taking the medicine with a meal — not just a snack — and drinking plenty of fluids eases some of the discomfort. Livers work harder with this drug; regular blood tests are part of the deal. The numbers matter. Catching a rise in liver enzymes early keeps the situation safer and sometimes lets you make a small change before big problems show up.
If trouble shows up, talking straight with healthcare teams matters much more than toughing it out. Many people fear getting taken off Pirfenidone if they complain. In real life, most doctors can cut the dose, adjust the timing, or recommend simple tricks to help you stay on track. Sometimes, switching up other medicines or habits, like spacing doses out a bit more or rearranging meals, does the trick.
No one nails the routine the first week. Pillboxes, reminders, and making the medicine part of a daily ritual — next to the coffee maker or toothbrush — cuts down on missed doses. In families I’ve worked with, someone takes on the nagging role—helpful, not annoying—and this keeps things running smoother. It’s a lot less about getting everything perfect, and a lot more about making the routine fit real life.
Taking pirfenidone can help slow down lung scarring in people with idiopathic pulmonary fibrosis. Yet mixing medicines is anything but straightforward. Many people juggling a chronic disease already take a few pills a day—blood pressure drugs, statins, metformin, or maybe over-the-counter painkillers. Every time a new drug comes into that mix, it has ripple effects. Some get lucky and feel fine. Others run into nasty surprises like sunburn, dizziness, vomiting, or even bigger problems like liver injury.
Experience shows that pirfenidone isn’t likely to cause trouble with every pill in your cabinet. The real risk comes from a handful of drugs that block certain liver enzymes. The liver does the heavy lifting of breaking down pirfenidone, mostly using a protein called CYP1A2. Medicines that slow this process can make pirfenidone build up to dangerous levels. For example—fluvoxamine, used often for depression or OCD, throws a big wrench into how pirfenidone gets cleared from the body. People taking both can end up with way more pirfenidone in their system than expected. The risk isn’t just theoretical. Clinical studies flagged this drug pair years ago. Fluvoxamine gets a bright red warning flag in medical guidelines for anyone taking pirfenidone.
Ciprofloxacin is another common culprit. Many people have been prescribed it for urinary or respiratory infections and may not remember all the details once the bottle runs out. This antibiotic also slows down liver processing, so doctors are told to cut the dose of pirfenidone in half if both drugs need to be given. Even a craft beer or cigarette can nudge CYP1A2 activity. Smoking speeds the process up, dropping pirfenidone levels and cutting its impact—which means smoking users may need different dosing for the medicine to work.
It’s easy for people to overlook non-prescription medicines and supplements. St. John’s Wort, for example, has the reputation of being “natural” but can change the way many drugs get processed. Grapefruit juice, another innocent-seeming item, rarely appears in these warnings but can mess with many medications, especially those moved through other liver enzymes, so asking the pharmacist never hurts.
Doctors get a tough job here: juggling the need to treat several problems at once without letting the solution for one cause a new problem somewhere else. Paperwork from pharmacists piles up, warning about interactions, but speaking as someone who’s seen plenty of prescriptions, folks often trust the pharmacist to just “catch problems.” Yet every visit brings up half-remembered bottle names and mystery supplements that rarely make it onto the list. Being honest and specific about every capsule, drink, and herbal tea is one of the best tools people have.
Patients shouldn’t have to play detective across ten pharmacy pamphlets. Pharmacies and clinics can use software that auto-alerts doctors and pharmacists about dangerous combinations. This technology already exists and works when the full medicine list is up-to-date. Medication reviews—where people have a frank, regular sit-down to go through every bottle and supplement—help catch hidden risks before they turn into side effects or hospital visits.
Clear, regular conversations still matter most. People who check in with their care team before adding or stopping any drug tend to avoid big surprises. Every medicine-check should include asking about sunlight sensitivity, nausea, unexplained bruising, or new fatigue—any of these can be a tip-off that drugs are clashing. Small steps add up to safer lives for people who need pirfenidone and other complex medications.
Pulmonary fibrosis slices through a person’s life in a way that’s both swift and quiet. Scar tissue replaces healthy lung tissue, making breathing harder and yardwork feel like mountain climbing. Doctors have searched for something—anything—that could slow this grinding process. Pirfenidone turned up as a contender, and folks living with this disease have pinned a lot of hope on it.
This medication doesn’t claim miracles. It targets the pathway that causes lung tissue to stiffen, aiming to tamp down swelling, limit scarring, and keep the lungs as open as possible for as long as possible. Reports from clinical trials and patient stories point to real, measurable slowing in the rate of lung function loss. More oxygen means more stories read to grandkids and one more fishing trip.
Studies funded in several countries checked the change in forced vital capacity (how much air one can exhale after a deep breath) as a marker. Adult patients saw about 30% less lung function lost over a year, which isn’t a cure, but it does draw a line in the sand against the disease’s usual sledgehammer pace. The FDA gave it a nod years ago, not just because of these numbers, but because the alternatives offer so little.
Now, not everyone feels better on Pirfenidone. Sunburn comes easier, appetite shrivels, and a dull nausea can turn up out of nowhere. For older folks juggling medications for blood pressure or diabetes, adding this drug means paying close attention to side effects. Those in rural areas wrestle with how to pay for a pill that can cost thousands monthly; insurance companies still push back in some states. Access shouldn’t depend on a zip code, but it does.
Folks living with pulmonary fibrosis want more than just “slowing down.” They want their lungs back. Researchers dig deeper into how scars form, searching for a way to undo the damage. The National Institutes of Health pumps cash into labs testing new drugs and mixes. Trials are recruiting every year—if you live close to a large medical center, you might see billboards looking for volunteers.
Community support plays a role, too. Group meetings—sometimes just a handful of people in a library basement—share advice on navigating drug programs, dealing with insurance paperwork, and finding ways to exercise that don’t leave one gasping. People who know what it’s like to lose their wind can offer insights a doctor can miss in a twenty-minute appointment.
People want more than just a few months tacked on; they long for a breakthrough. Until researchers turn that hope into reality, Pirfenidone keeps many from downhill slides that used to feel inevitable. Closer ties between scientists, insurers, and everyday patients will make solutions possible, so no one loses their breath—and their years—without a fair fight.
| Names | |
| Preferred IUPAC name | 5-methyl-1-phenylpyridin-2(1H)-one |
| Other names |
Esbriet Pirespa Pirfenex Kastipir Fibrodone |
| Pronunciation | /pɜːrˈfɛnɪˌdoʊn/ |
| Identifiers | |
| CAS Number | 53179-13-8 |
| Beilstein Reference | 1365047 |
| ChEBI | CHEBI:91254 |
| ChEMBL | CHEMBL1509 |
| ChemSpider | 2334100 |
| DrugBank | DB04951 |
| ECHA InfoCard | 03f8c24b-8187-4027-ab68-5f9b5f7aa353 |
| EC Number | 2.3.4.1 |
| Gmelin Reference | 643242 |
| KEGG | D02261 |
| MeSH | D000077378 |
| PubChem CID | 40632 |
| RTECS number | YQ079A106G |
| UNII | LVF29U68A1 |
| UN number | UN3249 |
| Properties | |
| Chemical formula | C12H11NO |
| Molar mass | 185.216 g/mol |
| Appearance | White to pale yellow crystalline powder |
| Odor | Odorless |
| Density | 1.0 g/cm³ |
| Solubility in water | Sparingly soluble |
| log P | 2.4 |
| Vapor pressure | 6.7E-7 mmHg |
| Acidity (pKa) | 6.06 |
| Basicity (pKb) | 7.05 |
| Magnetic susceptibility (χ) | -62.6×10^-6 cm³/mol |
| Refractive index (nD) | 1.523 |
| Viscosity | Viscous liquid |
| Dipole moment | 2.60 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 311.1 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -3587 kJ/mol |
| Pharmacology | |
| ATC code | J01XX08 |
| Hazards | |
| Main hazards | May cause liver injury, photosensitivity reaction, and gastrointestinal disturbances. |
| GHS labelling | GHS02, GHS07, GHS08 |
| Pictograms | [Pictograms: D, G, Xn] |
| Signal word | Warning |
| Hazard statements | H302, H319, H335 |
| Precautionary statements | P264, P280, P301+P312, P305+P351+P338, P337+P313 |
| Flash point | 110°C |
| Autoignition temperature | 320°C |
| Lethal dose or concentration | LD50 (rat, oral): 1,290 mg/kg |
| LD50 (median dose) | LD50 (median dose) of pirfenidone is 1297 mg/kg (oral, rat) |
| NIOSH | VX8R8K0O0Y |
| PEL (Permissible) | Not established |
| REL (Recommended) | 40 mg/kg/day |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
5-Methyl-1-phenyl-2-(1H)-pyridone Thalidomide Lenalidomide Pomalidomide |
